These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

958 related articles for article (PubMed ID: 17852143)

  • 1. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
    Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of the effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on blood coagulability.
    Skouby SO; Sidelmann JJ; Nilas L; Jespersen J
    Hum Reprod; 2007 Apr; 22(4):1186-91. PubMed ID: 17204528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
    Christodoulakos G; Lambrinoudaki I; Panoulis C; Sioulas V; Rizos D; Caramalis G; Botsis D; Creatsas G
    Maturitas; 2005 Apr; 50(4):321-30. PubMed ID: 15780533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women.
    Osmanağaoğlu MA; Osmanağaoğlu S; Osmanağaoğlu T; Okumuş B; Bozkaya H
    Fertil Steril; 2005 Aug; 84(2):384-93. PubMed ID: 16084879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors.
    Skouby SO; Sidelmann JJ; Nilas L; Gram J; Jespersen J
    Climacteric; 2008; 11(6):489-97. PubMed ID: 18991076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
    Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
    Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive function variations in postmenopausal women treated with continuous, combined HRT or tibolone. A comparison.
    Pan HA; Wang ST; Pai MC; Chen CH; Wu MH; Huang KE
    J Reprod Med; 2003 May; 48(5):375-80. PubMed ID: 12815913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of hormone replacement therapy and tibolone on serum leptin levels in postmenopausal women.
    Lambrinoudaki IV; Christodoulakos GE; Panoulis CP; Rizos DA; Dendrinos SG; Liakakos T; Augoulea AD; Creatsas GC
    Maturitas; 2004 Jun; 48(2):107-13. PubMed ID: 15172084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conjugated estrogen/progestagen versus tibolone hormone replacement therapy in postmenopausal women: Effects on carbohydrate metabolism and serum sex hormone-binding globulin.
    Odmark IS; Carlström K; Jonsson B; Jonasson AF
    Maturitas; 2006 Jan; 53(1):89-96. PubMed ID: 15964160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding.
    Yildirim G; Tugrul S; Uslu H; Pekin O; Eren S
    Arch Gynecol Obstet; 2006 Feb; 273(5):268-73. PubMed ID: 16315025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating leptin and ghrelin are differentially influenced by estrogen/progestin therapy and raloxifene.
    Lambrinoudaki IV; Christodoulakos GE; Economou EV; Vlachou SA; Panoulis CP; Alexandrou AP; Kouskouni EE; Creatsas GC
    Maturitas; 2008 Jan; 59(1):62-71. PubMed ID: 18164562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow resistance in carotid and middle cerebral arteries in postmenopausal women: a comparative study of tibolone and continuous combined hormone replacement therapy.
    Pan HA; Wang ST; Chen CH; Pai MC; Wu MH; Huang KE
    Climacteric; 2002 Sep; 5(3):259-65. PubMed ID: 12419084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effect of hormone therapy and tibolone on lipids, lipoproteins, and the atherogenic index of plasma.
    Christodoulakos GE; Lambrinoudaki IV; Economou EV; Papadias C; Panoulis CP; Kouskouni EE; Vlachou SA; Creatsas GC
    J Cardiovasc Pharmacol; 2006 Apr; 47(4):542-8. PubMed ID: 16680067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women.
    Christodoulakos GE; Lambrinoudaki IV; Creatsa MG; Economou EV; Siasou Z; Panoulis CP; Kalligerou I; Papadias C
    Climacteric; 2008 Apr; 11(2):155-65. PubMed ID: 18365858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of low dose hormone therapy on mammographic breast density.
    Christodoulakos GE; Lambrinoudaki IV; Vourtsi AD; Vlachou S; Creatsa M; Panoulis KP; Botsis D
    Maturitas; 2006 Apr; 54(1):78-85. PubMed ID: 16198519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term effects of hormone therapy on serum C-reactive protein levels in postmenopausal women.
    Kiran H; Kiran G
    Arch Gynecol Obstet; 2006 Apr; 274(1):9-12. PubMed ID: 16369811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
    Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
    Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
    Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
    Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
    Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
    Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.